<qa>  What is the name of the treatment that has received treatment with?All patients with CML in any phase of the disease chronic, accelerated or blast phase that has received treatment with any tyrosine kinase inhibitor eg, imatinib, dasatinib, nilotinib regardless of prior treatment history that has had at least one clinic visit at MDACC will be eligible. 